Comparison of Side Effects of ARNI vs ACEi/ARB in Heart Failure Therapy
Analysis
DOI:
https://doi.org/10.55175/cdk.v52i5.1314Keywords:
ACEi, ARB, ARNI, heart failureAbstract
Introduction: Pharmacological treatment of heart failure continues to develop. Newer drugs such as ARNI (angiotensin receptor neprilysin inhibitor) have become standard for heart failure treatment. This systematic review aims to compare the side efects of ARNI with those of previous standard heart failure therapy. Methods: This research uses PRISMA rules to analyze articles from PubMed and Cochrane. Results: A total of 2,741 articles, excluding duplicates, were selected for title and abstract screening. Twelve articles met the requirements for thorough screening. Of the 12 articles, 4 articles were selected for systematic review analysis. There were 6,553 samples, 2,580 in the ARNI group and 2,390 in the ACEI/ARB group. ARNI was better in reducing the risk of decreased eGFR (RR: 0.51; 0.34-0.78) and the incidence of hyperkalemia (RR: 0.87; 0.76-0.99) but the risk of symptomatic hypotension was greater in the ARNI group (RR: 1.47; 1.23-1.70). Conclusion: The risk of hypotension as well as a reduced risk of cardiovascular death and rehospitalization was higher in the ARNI group, while the risk of decreased eGFR and hyperkalemia was higher in the ACEi/ARB group.
Downloads
References
Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal defnition and classifcation of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Defnition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 2021;23(3):352–80. DOI: 10.1002/ejhf.2115.
Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: A comprehensive and updated review of epidemiology. Cardiovasc Res 2023;118(17):3272–87. DOI: 10.1093/cvr/cvac013.
Jering K, Claggett B, Redfeld MM, Shah SJ, Anand IS, Martinez F, et al. Burden of heartfailure signs and symptoms, prognosis, and response to therapy. JACC Heart Fail 2021;9(5):386–97. DOI: 10.1016/j.jchf.2021.01.011.y
Malik A, Chhabra L. Congestive heart failure. [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. [cited 2024 April 4]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430873/. PMID: 28613623
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2022;145(18):895–1032. DOI: 10.1161/CIR.0000000000001063.
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371(11):993–1004. DOI: 10.1056/NEJMoa1409077.
Velazquez EJ, Morrow DA, DeVore AD, Dufy CI, Ambrosy AP, McCague K, et al. Angiotensin–neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019;380(6):539–48. DOI: 10.1056/NEJMoa1812851.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hofmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021;372:1–9. DOI: 10.1136/bmj.n71.
Rayyan faster systematic reviews [Internet]. 2022 [cited 2024 March 25]. Available from: https://rayyan.ai
Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, et al. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol 2023;82(1):1–12. DOI: 10.1016/j.jacc.2023.04.019.
Berg DD, Braunwald E, DeVore AD, Lala A, Pinney SP, Dufy CI, et al. Efcacy and safety of sacubitril/valsartan by dose level achieved in the PIONEER-HF Trial. JACC Heart Fail 2020;8(10):834–43. DOI: 10.1016/j.jchf.2020.06.008.
Solomon SD, McMurray JJV, Anand IS, Phil D, Ge J, Lam CSP, et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381(17):1609–20; DOI: 10.1056/NEJMoa1908655.
Sharma S, Hashmi MF, Bhattacharya PT. Hypotension. [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. [cited 2024 May 24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499961/
Inamdar AA, Inamdar AC. Heart failure: Diagnosis, management and utilization. J Clin Med 2016;5(7):1–28; DOI: 10.3390/jcm5070062.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA Guideline for the management of heart failure. Circulation 2013;128(16):240–327; DOI: 10.1161/CIR.0b013e31829e8776.
Bano S, Bai P, Kumar S, Kumar N, Ali A, Pariya F, et al. Comparison of sacubitril/valsartan versus enalapril in the management of heart failure. Cureus 2021;13:1–5. DOI: 10.7759/cureus.16332.
Duan Y, Yu M, Xu Y. Efect of sacubitril-valsartan on chronic systolic heart failure and its efect on LVEF, 6-MWT, NT proBNP and NT proBNP/BNP levels. Trop J Pharmaceut Res 2023;22(6):1335–40.
Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, et al. Renal Efects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 2018;6(6):489–98. DOI: 10.1016/j.jchf.2018.02.004.
Mc Causland FR, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, Gori M, et al. Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation 2020;142(13):1236–45. doi: 10.1161/CIRCULATIONAHA.120.047643.
Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, et al. Efcacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGMHF trial. Eur J Heart Fail 2016;18(10):1228–34. DOI: 10.1002/ejhf.580.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Anjar Nuryanto
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
